

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 00250.74943	SERIAL NUMBER 09/203,676
	APPLICANT Michael R. Zalusky	
	FILING DATE December 1, 1998	GROUP ART UNIT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
KAC	5,541,297	7/30/1996	Hansen et al.	—	—	—
KAC	5,302,700	4/12/1994	Zalutsky et al.	—	—	—
KAC	4,885,153	12/5/1989	Wilbur et al.	—	—	—

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES/NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	Michael R. Zalutsky, "Astatine and Iodine Radiolabeled Monoclonal Antibodies" CRISPAbstract to NIH Grant 5R01CA42324-12 (published June 24, 1994) < ">http://commons.cit.nih.gov/crisp_historical/owa/crisp_lib.getdoc?textkey=2330729&p_grant_num=5R01CA42324-12&p_query=&ticket=130238&p_audit_session_id=57936&p_keywords=>
KAC	"Immunomedics Awarded U.S. Patent for Therapeutic Conjugates of Toxins and Drugs Immunomedics Invents New Targeted Therapies for Cancers and Infectious Diseases" PR Newswire via Individual, Inc., August 14, 1996
KAC	C.J. Reist et al. "Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate" Cancer Res. 1996 No. 1;56(21:4970-7 November 1, 1996
KAC	C.J. Reist et al. "In Vitro and In Vivo Behavior of Radiolabeled Chimeric Anti-EGFRvIII Monoclonal Antibody: Comparison with its Murine Patent" Nuclear Medicine & Biology, Vol. 24, pages 639-647 1997
KAC	S.R. Govindan et al. "A non-metabolizable TPA-peptide (DPEP) approach for production of a residualizing Iodine radiolabeled for targeting human lung cancer xenografts" Proceedings of the American Association for Cancer Research, Vol. 39, March 1996 #2585 (Abstract)
KAC	S.V. Govindan et al. "Peptide-based Residualizing Radioiodine Labels for Radioimmunotherapy" Journal of Nuclear Medicine, Vol. 39, No. 5, May 1998 No. 989 (Abstract)
KAC	C.J. Reist et al. "Improved Targeting of an Anti-Epidermal Growth Factor Receptor Variant III Monoclonal Antibody in Tumor Xenografts after Labeling Using N-Succinimidyl 5-Iodo-3-Pyridinecarboxylate" Cancer Research 57, 1510-1515 April 15, 1997

EXAMINER <i>Karen A. Gamble</i>	DATE CONSIDERED <i>5/18/00</i>
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	